We advised Biocytogen on its IPO and SSE listing

Davis Polk advised Biocytogen Pharmaceuticals (Beijing) Co., Ltd. in connection with its initial public offering and listing on the Science and Technology Innovation Board of the Shanghai Stock Exchange. The gross proceeds from the offering amounted to approximately RMB1.27 billion. This marks the first case of an H-share-to-A-share listing since 2024.

Davis Polk also advised Biocytogen on its HK$549 million IPO in September 2022. The shares are listed on the Hong Kong Stock Exchange.

Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics, to explore global partnerships for an off-the-shelf library of more than 1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration.

The Davis Polk corporate team included partners Xuelin (Steve) Wang and Jason Xu, counsel Vanessa Chan and associate Marco Cheng. Members of the Davis Polk team are based in the Hong Kong and Beijing offices.

Copy link to share post